In small test, experimental prostate drug shows promise
An experimental drug is showing what some experts say is intriguing effectiveness in treating a major cause of death and disability for men with prostate cancer — tumors that have spread to the bone.
The results of early testing of the drug, to be presented at a cancer conference in Berlin on Thursday, would be another piece of good news this week for men with the disease. On Wednesday, a federal advisory committee said there was adequate evidence that the already marketed prostate cancer drug Provenge, developed by Dendreon, prolongs lives.
- Healthcare Leaders Seek Strategic Sweet Spot
- 3 Reasons Wellness Programs Fail
- CMS Issues Health Insurance Exchange Proposed Rules
- Patients Shoulder Nearly 25% of Medical Bills
- ACOs Widespread, Yet Challenged
- MGMA: Physician Compensation Increasingly Based on Quality Measures
- Healthcare Costs 'An Abomination' Says Senate Finance Committee Chair
- 6 CNO-to-CEO Strategies
- Healthcare Consolidation: M&A Not the Only Way
- PwC: Pace of Rising Medical Costs Slowing